evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,756 questions · 11,779 findings · 747 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3,205 · 27.2%GRADE not reported 628 · 5.3%Very low 3,261 · 27.7%Low 2,913 · 24.7%Moderate 1,453 · 12.3%High 319 · 2.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Antioxidants vs placebo

Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis

It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).

1 finding from 1 review

PUFA vs monounsaturated fatty acid (MUFA)

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).

1 finding from 1 review

Omega‐3 vs omega‐6

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).

1 finding from 1 review

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).

1 finding from 1 review

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).

1 finding from 1 review

Paradoxical intention therapy vs diazepam

Reduction in physical signs (number of patients without any conversive attacks in last 2 weeks) End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

It is very uncertain whether paradoxical intention therapy changes reduction in physical signs (number of patients without any… compared with diazepam (very low certainty).

1 finding from 1 review